{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:21:08Z","timestamp":1784744468564,"version":"3.55.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009360","name":"King\u2019s College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"MRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["094849\/Z\/10\/Z"],"award-info":[{"award-number":["094849\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC- A656-5QD30"],"award-info":[{"award-number":["MC- A656-5QD30"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012176","name":"Maudsley Charity","doi-asserted-by":"publisher","award":["666"],"award-info":[{"award-number":["666"]}],"id":[{"id":"10.13039\/100012176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.neubiorev.2022.104568","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T02:15:03Z","timestamp":1643940903000},"page":"104568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"135","author":[{"given":"Martin","family":"Osugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Whitehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Shatalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oisin","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz Lun Allenis","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.neubiorev.2022.104568_bib1","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104568_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III--the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophrenia Bull."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104568_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis","volume":"44","author":"McCutcheon","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2019.07.008","article-title":"Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance","volume":"87","author":"Brugger","year":"2020","journal-title":"Biological Psychiatry."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia: A Positron Emission Tomographic Functional Magnetic Resonance Imaging Study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104568_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/bjp.bp.113.132308","article-title":"Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies","volume":"204","author":"Kambeitz","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104568_bib9","article-title":"Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis","author":"Plav\u00e9n-Sigray","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104568_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104568_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1017\/S1092852918001050","article-title":"Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder","volume":"24","author":"Solmi","year":"2019","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neubiorev.2022.104568_bib14","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT GSe","year":"2008"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104568_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/JCP.0000000000001124","article-title":"Prodopaminergic drugs for treating the negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Sabe","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104568_bib16","unstructured":"Fu RHH, 2015, Change Score or Followup Score? An Empirical Evaluation of the Impact of Choice of Mean Difference Estimates. Agency for Healthcare Research and Quality."},{"key":"10.1016\/j.neubiorev.2022.104568_bib17","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104568_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","article-title":"A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities","volume":"147","author":"Lindenmayer","year":"2013","journal-title":"Schizophrenia Res."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104568_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204056","article-title":"Bias caused by sampling error in meta-analysis with small sample sizes","volume":"13","author":"Lin","year":"2018","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology ((Berl))"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104568_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S0266462312000086","article-title":"The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies","volume":"28","author":"Morrison","year":"2012","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.neubiorev.2022.104568_bib22","unstructured":"WebPlotDigitizer, Version Version 4.3. Pacifica; 2017."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib23","first-page":"48","article-title":"Conducting Meta-Analyses in R with the metafor Package. 2010","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"2010-08-05"},{"issue":"7109","key":"10.1016\/j.neubiorev.2022.104568_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.neubiorev.2022.104568_bib25","unstructured":"Harrer M., Cuijpers P., Furukawa TA, Ebert DD. Doing meta-analysis in R: A hands-on guide. PROTECT Lab Erlangen. 2019."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc.: Ser. B (Methodological)"},{"issue":"17","key":"10.1016\/j.neubiorev.2022.104568_bib27","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib28","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia","volume":"177","author":"Leucht","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104568_bib29","first-page":"464","article-title":"The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis","volume":"59","author":"Rosenberg","year":"2005","journal-title":"Evolution."},{"key":"10.1016\/j.neubiorev.2022.104568_bib30","unstructured":"Euctr GR Effectiveness of tolcapone in schizophrenia. \u3008http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2013\u2013002713-35-GR\u3009. 2014;"},{"key":"10.1016\/j.neubiorev.2022.104568_bib31","unstructured":"Euctr NL Brain activation by addition of L-Dopa to normal antipsychotic treatment in patients with schizophrenia. \u3008http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2010\u2013019897-33-NL\u3009. 2010;"},{"key":"10.1016\/j.neubiorev.2022.104568_bib32","unstructured":"Nct. Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder. \u3008https:\/\/clinicaltrialsgov\/show\/NCT01320982\u3009. 2011;"},{"key":"10.1016\/j.neubiorev.2022.104568_bib33","unstructured":"Nct. Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia. \u3008https:\/\/clinicaltrialsgov\/show\/NCT00580125\u3009. 2007."},{"key":"10.1016\/j.neubiorev.2022.104568_bib34","unstructured":"Nct. Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder. \u3008https:\/\/clinicaltrialsgov\/show\/NCT00139919\u3009. 2005."},{"key":"10.1016\/j.neubiorev.2022.104568_bib35","unstructured":"Nct. To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox. \u3008https:\/\/clinicaltrialsgov\/show\/NCT00141479\u3009. 2005."},{"key":"10.1016\/j.neubiorev.2022.104568_bib36","unstructured":"Nct. Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia. \u3008https:\/\/clinicaltrialsgov\/show\/NCT00139906\u3009. 2005."},{"key":"10.1016\/j.neubiorev.2022.104568_bib37","unstructured":"Nct. Bifeprunox in the Treatment of Schizophrenia. \u3008https:\/\/clinicaltrialsgov\/show\/NCT00193713\u3009. 2005."},{"issue":"Suppl 1","key":"10.1016\/j.neubiorev.2022.104568_bib38","first-page":"S251","article-title":"A randomized, double-blind, placebo-controlled study of bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia","volume":"31","author":"Barbato","year":"2006","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.neubiorev.2022.104568_bib39","unstructured":"Euctr ES. Evaluation of Tolcapone As a Cognitive Enhancer in Schizophrenia. \u3008http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2010\u2013024119-15-ES\u3009. 2014."},{"key":"10.1016\/j.neubiorev.2022.104568_bib40","unstructured":"Nct. Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia. \u3008https:\/\/clinicaltrialsgov\/show\/NCT01066403\u3009. 2010."},{"key":"10.1016\/j.neubiorev.2022.104568_bib41","unstructured":"Nct. Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia. \u3008https:\/\/clinicaltrialsgov\/show\/NCT00197483\u3009. 2005."},{"key":"10.1016\/j.neubiorev.2022.104568_bib42","unstructured":"Euctr GR. A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patiens with stable schizophrenia - N\/A. \u3008http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2005\u2013005499-34-GR\u3009. 2007."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104568_bib43","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Kane","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104568_bib44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104568_bib45","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104568_bib46","article-title":"Aripiprazole, a new typical antipsychotic: phase 2 clinical trial result","volume":"1997","author":"Petrie","year":"1997","journal-title":"10th european college of neuropsychopharmacology congress Vienna, austria 13th-17th september"},{"issue":"suppl 1","key":"10.1016\/j.neubiorev.2022.104568_bib47","first-page":"S157","article-title":"Aripiprazole, a novel antipsychotic: overview of a phase II study result","volume":"3","author":"Daniel","year":"2000","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104568_bib48","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104568_bib49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S1092852900014784","article-title":"The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia","volume":"11","author":"Cutler","year":"2006","journal-title":"CNS Spectr."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104568_bib50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia","volume":"41","author":"McEvoy","year":"2007","journal-title":"J. Psychiatr. Res."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104568_bib51","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104568_bib52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104568_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.schres.2017.01.043","article-title":"Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder","volume":"189","author":"Cantillon","year":"2017","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104568_bib54","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104568_bib55","unstructured":"Euctr, S.K., 2009, A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia. \u3008http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2009\u2013012567-33-SK\u3009."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104568_bib56","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib57","first-page":"11","article-title":"Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study","volume":"20","author":"Fleischhacker","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104568_bib58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pcn.12682","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104568_bib59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr Res."},{"key":"10.1016\/j.neubiorev.2022.104568_bib60","unstructured":"Nct, 2013, Brexpiprazole in Patients With Acute Schizophrenia. \u3008https:\/\/clinicaltrialsgov\/show\/NCT01810380\u3009."},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2022.104568_bib61","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophr Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104568_bib62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","author":"Durgam","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2022.104568_bib63","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2022.104568_bib65","series-title":"Proc. 11th Int. Congress Schizophrenia Res.","article-title":"Efficacy and safety of bifeprunox in preventing deterioration in patients with stable schizophrenia: results from a 6-month placebo-controlled study","author":"Bourin","year":"2007"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib66","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","volume":"200","author":"Casey","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104568_bib67","unstructured":"Euctr BG. A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. - N\/A. \u3008http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2007\u2013001097-90-BG\u3009. 2008."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104568_bib68","first-page":"446","article-title":"A randomized, double-blind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia","volume":"33","author":"Meltzer","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0006-3223(97)00030-9","article-title":"Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov\u2019t, P.H.S","volume":"43","author":"Lahti","year":"1998","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib70","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-011-2513-z","article-title":"A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia","volume":"220","author":"Arbabi","year":"2012","journal-title":"Psychopharmacology ((Berl))"},{"issue":"12","key":"10.1016\/j.neubiorev.2022.104568_bib71","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.08m04683","article-title":"Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial","volume":"70","author":"Freudenreich","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib72","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2013.07.039","article-title":"Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study","volume":"150","author":"Lohr","year":"2013","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.neubiorev.2022.104568_bib73","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.euroneuro.2015.03.009","article-title":"Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia","volume":"25","author":"Michalopoulou","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104568_bib74","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/npp.2015.271","article-title":"Sustained modafinil treatment effects on control-related gamma oscillatory power in schizophrenia","volume":"41","author":"Minzenberg","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2022.104568_bib75","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4088\/JCP.v68n0507","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia","volume":"68","author":"Pierre","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104568_bib76","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4088\/JCP.v66n0705","article-title":"Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications","volume":"66","author":"Sevy","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JCP.0000000000000437","article-title":"Intractability of deficit syndrome of schizophrenia against adjunctive modafinil","volume":"36","author":"Shoja Shafti","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104568_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.schres.2011.05.015","article-title":"The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia\/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial","volume":"130","author":"Bobo","year":"2011","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104568_bib79","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4088\/JCP.09m05950gry","article-title":"Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study","volume":"71","author":"Kane","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2022.104568_bib80","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2011.11.006","article-title":"Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study","volume":"135","author":"Kane","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2004.12.019","article-title":"Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers","volume":"77","author":"Barch","year":"2005","journal-title":"Schizophrenia Res."},{"issue":"11","key":"10.1016\/j.neubiorev.2022.104568_bib82","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/npp.2013.111","article-title":"Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases","volume":"38","author":"Lasser","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104568_bib83","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JCP.0000000000000205","article-title":"Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses","volume":"34","author":"Martin","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib84","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hup.1118","article-title":"Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia","volume":"25","author":"Pietrzak","year":"2010","journal-title":"Hum. Psychopharmacol.-Clin. Exp."},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104568_bib85","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02246180","article-title":"Amphetamine and negative symptoms of schizophrenia","volume":"123","author":"Sanfilipo","year":"1996","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.neubiorev.2022.104568_bib86","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0006-3223(97)00052-8","article-title":"Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: Implications for a sensitization model of psychosis in humans","volume":"42","author":"Strakowski","year":"1997","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib87","first-page":"221","article-title":"Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms","volume":"23","author":"Chouinard","year":"1987","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00421193","article-title":"The effect of L dopa on young patients with simple schizophrenia, treated with neuroleptic drugs A double blind cross over trial with Madopar and placebo","volume":"44","author":"Gerlach","year":"1975","journal-title":"Psychopharmacologia."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib89","first-page":"204","article-title":"L-dopa helps positive but not negative features of neuroleptic-insensitive chronic schizophrenia","volume":"8","author":"Owens","year":"1994","journal-title":"J.: Article. J. Psychopharmacol. (Oxford, England)"},{"issue":"1","key":"10.1016\/j.neubiorev.2022.104568_bib90","first-page":"55","article-title":"Apomorphine reduces schizophrenic symptoms","volume":"16","author":"Schaffer","year":"1980","journal-title":"Psychopharmacol. Bull."},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib91","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/archpsyc.1986.01800040108015","article-title":"Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine","volume":"43","author":"Tamminga","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"issue":"FEB.","key":"10.1016\/j.neubiorev.2022.104568_bib92","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1192\/bjp.148.2.204","article-title":"Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics","volume":"148","author":"Syvalahti","year":"1986","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib93","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0006-3223(89)90172-8","article-title":"Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics","volume":"25","author":"Gattaz","year":"1989","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib94","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00428312","article-title":"Treatment of Schizophrenia with ergot derivatives","volume":"66","author":"Tamminga","year":"1979","journal-title":"Psychopharmacology ((Berl))"},{"issue":"2","key":"10.1016\/j.neubiorev.2022.104568_bib95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/npp.1994.40","article-title":"Methylphenidate response, psychopathology and tardive-dyskinesia as predictors of relapse in schizophrenia","volume":"11","author":"Lieberman","year":"1994","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2022.104568_bib96","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00004714-199208000-00010","article-title":"Methylphenidate augmentation therapy in schizophrenia","volume":"12","author":"Carpenter","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104568_bib97","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.euroneuro.2011.10.002","article-title":"Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment","volume":"22","author":"Kelleher","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.neubiorev.2022.104568_bib98","unstructured":"Nct, 2002, Clinical Trial of Tolcapone for Cognition in Schizophrenia. \u3008https:\/\/clinicaltrialsgov\/show\/NCT00044083\u3009."},{"key":"10.1016\/j.neubiorev.2022.104568_bib99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.09.013","article-title":"Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Andrade","year":"2015","journal-title":"J. Psychiatr. Res."},{"issue":"10202","key":"10.1016\/j.neubiorev.2022.104568_bib100","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104568_bib101","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104568_bib102","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2022.104568_bib103","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ijnp\/pyz017","article-title":"D1-Dopamine receptor availability in first-episode neuroleptic naive psychosis patients","volume":"22","author":"Stenkrona","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2022.104568_bib104","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-013-3232-4","article-title":"The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders","volume":"229","author":"Mereu","year":"2013","journal-title":"Psychopharmacology"},{"issue":"139","key":"10.1016\/j.neubiorev.2022.104568_bib105","article-title":"Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions. Review","volume":"4","author":"Wisor","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neubiorev.2022.104568_bib106","series-title":"MRMM. Dextroamphetamine-Amphetamine","author":"Sharbaf Shoar","year":"2021"},{"key":"10.1016\/j.neubiorev.2022.104568_bib107","series-title":"Tolcapone. StatPearls [Internet]","author":"Willman","year":"2021"},{"issue":"6","key":"10.1016\/j.neubiorev.2022.104568_bib108","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","article-title":"Dopamine agonists: their role in the treatment of Parkinson\u2019s disease","volume":"68","author":"BROOKS","year":"2000","journal-title":"J. Neurol., Neurosurgery Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.neubiorev.2022.104568_bib109","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.parkreldis.2016.12.003","article-title":"Apomorphine - pharmacological properties and clinical trials in Parkinson's disease","volume":"33","author":"Jenner","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"10074","key":"10.1016\/j.neubiorev.2022.104568_bib110","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.neubiorev.2022.104568_bib111","series-title":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews","article-title":"AHRQ Methods for Effective Health Care Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program","author":"Fu","year":"2008"},{"key":"10.1016\/j.neubiorev.2022.104568_bib112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.schres.2016.02.035","article-title":"Current developments and challenges in the assessment of negative symptoms","volume":"186","author":"Lincoln","year":"2017","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.neubiorev.2022.104568_bib113","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00134-018-5293-7","article-title":"Industry sponsorship and research outcome: systematic review with meta-analysis","volume":"44","author":"Lundh","year":"2018","journal-title":"Intensive Care Med."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:09:45Z","timestamp":1758967785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763422000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":113,"alternative-id":["S0149763422000574"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104568","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104568"}}